Neurogenesis ((NEUN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeuroGenesis Ltd. is launching a Phase 2b clinical trial titled ‘A Double Blind, Randomized, Placebo Controlled Phase 2b Study to Evaluate the Safety and Clinical Efficacy of Treatment With the Autologous Cell Therapy Product, NG01, in Patients With Secondary Progressive Multiple Sclerosis.’ The study aims to assess the safety and effectiveness of NG01, a cell therapy product, in improving walking ability in patients with Secondary Progressive Multiple Sclerosis (SPMS).
The intervention being tested is NG01, an autologous bone marrow-derived human stromal cell therapy, administered intrathecally. The study will compare two doses of NG01 against a placebo to evaluate improvements in walking speed and the occurrence of adverse events.
This interventional study is designed as a randomized, parallel-assignment trial with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment-focused, aiming to deliver significant clinical insights into SPMS management.
The study is set to begin on April 21, 2025, with the primary completion date yet to be determined. The last update was submitted on April 28, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market implications of this study are significant, as positive results could enhance NeuroGenesis’ stock performance and investor confidence. The study’s outcomes may also influence the competitive landscape in the SPMS treatment market, potentially affecting other companies in the sector.
The study is currently not yet recruiting, and further details are available on the ClinicalTrials portal.